October 2021 OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104
October 2021 Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
October 2021 OSE Immunotherapeutics Awarded First Prize and “Listed Company” Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest
October 2021 OSE Immunotherapeutics to present the preclinical data of its new checkpoint inhibitor Effi-DEM
October 2021 OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director
October 2021 OSE Immunotherapeutics will present at the Rodman & Renshaw 18th Annual Global Investment Conference
October 2021 OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen